Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Inolimomab
Therapeutic Area : Immunology
Study Phase : Phase III
Recipient : ElsaLys Biotech
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Acquisition of ElsaLys Biotech adds drugs like Inolimomab and ELB011 to Mediolanum Farmaceutici's pipeline paving the way for its international expansion and increasing the Group's R&D capabilities.
Product Name : Leukotac
Product Type : Antibody
Upfront Cash : Undisclosed
July 05, 2020
Lead Product(s) : Inolimomab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Recipient : ElsaLys Biotech
Deal Size : Undisclosed
Deal Type : Acquisition